Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Date:8/28/2007
ood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.
Under the worldwide co- development and commercialization agreement entered into in June 2006, HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $92.5 million received to date and a $40 million payment expected in September 2007.
About Hepatitis C
Hepatitis C is an inflammation of the liver caused by the hepatitis C virus. An estimated 170 million people worldwide are infected with the virus, including nearly 4 million people in the United States. When detectable levels of the hepatitis C virus persist in the blood for at least six months, a person is diagnosed as having chronic hepatitis C. The hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death.
About Human Genome Sciences
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.
The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are under way.
In J
'/>"/>
| SOURCE Human Genome Sciences, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Apollos human proteins boost stem cell research
5. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Post Your Comments:
(Date:5/19/2013)... May 20, 2013 Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...
(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...
(Date:5/17/2013)... , May 17, 2013 Sorrento Therapeutics, ... its Fast-Track Advanced Technology Small Business Technology Transfer ... of Allergy and Infectious Diseases (NIAID), a division ... the development of novel human antibody therapeutics to ... or Staph) infections, including methicillin-resistant S. ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4[0] Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak[0] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm[0] Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
... today reported one year,survival results from a Phase I/II ... in combination with dacarbazine in,patients with unresectable stage III ... cohort of patients in both the Phase I and,Phase ... the entire patient,set and a 22 month overall mean ...
... (NYSE:,AZN) today announced that the company has submitted ... U.S. Food and Drug,Administration (FDA) for once-daily SEROQUEL ... the treatment of manic,episodes associated with bipolar disorder ... disorder., The bipolar mania submission is based ...
Cached Medicine Technology:AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 2AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 3AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 4AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 2AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 3AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 4AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 5AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 6AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 7(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest Medicaid ... has earned a Commendable Accreditation status from the ... is a wholly owned subsidiary of Horizon Blue Cross ... Plan Accreditation is a nationally recognized program that evaluates ... provide to their members. Health Plan Accreditation performance results ...
(Date:5/20/2013)... May 20, 2013 The American Society ... for Bright Pink®, the organization that empowers young women to ... end of 2012. Thanks to its members, ASCP raised more ... is involved in Relay for Life at the local level. ... he decided to donate. “I was made aware of the ...
(Date:5/20/2013)... New York (PRWEB) May 20, 2013 The ... new study has found that magnetic resonance imaging (MRI) can ... regardless of whether or not patients are experiencing symptoms. ... Journal of Bone & Joint Surgery, MRI detected synovitis ... In patients suffering symptoms due to mechanical causes, the detection ...
(Date:5/20/2013)... , , MONDAY, May 20 (HealthDay News) -- Boys who ... as likely to become obese adults as those who ... new 30-year study shows. Researchers found that men ... index (BMI) and obesity, even if they no longer ... well-off or poor, they tended toward obesity. ...
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- The older vaccine ... late 1990s is more effective than the current version ... who received four shots with the older vaccine -- ... old were significantly less likely to become infected with ... to children who received all of their immunizations with ...
Breaking Medicine News(10 mins):Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3[0] Horizon NJ Health Awarded Commendable Accreditation by NCQA[0] ASCP Members Rally Around Breast and Ovarian Cancer Awareness[0] Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure[0] ADHD in Childhood May Raise Risk for Obesity in Adulthood[0] Study: Older Whooping Cough Vaccine More Effective
... is observed that breathing oxygen may cause some harm to ... beds of people //with severe lung or heart disease.Oxygen supports ... enough through the blood. But oxygen is often given inappropriately. ... 'breathe of life'. ,A study by researchers at New ...
... observed that approximately two thirds of teenage boys and ... suffer from at least// one psychiatric disorder. In ... evaluated by researchers before they were admitted to a ... interviewed the juvenile teens in order to track the ...
... Researchers have found that two types of scan are ... of ovarian cancer within the abdominal cavity. Positron emission ... of tumour tissue, while computed tomography (CT) is good ... School have found that combining the two detects ovarian ...
... an artificial disc to replace damaged spinal discs has successfully ... by discs of cartilage which serve as a cushion between ... two spinal bones may grind together, giving rise to acute ... disc is to remove it and fuse the two spinal ...
... with severe respiratory disease can walk further, and are less ... is key to pulmonary// rehabilitation in people who develop severe ... can walk in a fixed time and this helps them ... Ohio State University now report on the beneficial effect of ...
... coping style helps women to deal positively with breast cancer. ... difference in the fight against cancer. Researchers in the US ... stress, mental outlook and coping style are all relevant to ... ,They found that up to 44 per cent of ...
Cached Medicine News:... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |